We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
A Phase 3, Randomized, Double-Blind Study Comparing Tedizolid Phosphate and Linezolid for Treatment of Ventilated Gram-Positive Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia.
- Authors
Wunderink, Richard G; Roquilly, Antoine; Croce, Martin; Gonzalez, Daniel Rodriguez; Fujimi, Satoshi; Butterton, Joan R; Broyde, Natasha; Popejoy, Myra W; Kim, Jason Y; Anda, Carisa De
- Abstract
Background Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) are associated with high mortality rates. We evaluated the efficacy and safety of tedizolid (administered as tedizolid phosphate) for treatment of gram-positive ventilated HABP/VABP. Methods In this randomized, noninferiority, double-blind, double-dummy, global phase 3 trial, patients were randomized 1:1 to receive intravenous tedizolid phosphate 200 mg once daily for 7 days or intravenous linezolid 600 mg every 12 hours for 10 days. Treatment was 14 days in patients with concurrent gram-positive bacteremia. The primary efficacy end points were day 28 all-cause mortality (ACM; noninferiority margin, 10%) and investigator-assessed clinical response at test of cure (TOC; noninferiority margin, 12.5%) in the intention-to-treat population. Results Overall, 726 patients were randomized (tedizolid, n = 366; linezolid, n = 360). Baseline characteristics, including incidence of methicillin-resistant Staphylococcus aureus (31.3% overall), were well balanced. Tedizolid was noninferior to linezolid for day 28 ACM rate: 28.1% and 26.4%, respectively (difference, –1.8%; 95% confidence interval [CI]: –8.2 to 4.7). Noninferiority of tedizolid was not demonstrated for investigator-assessed clinical cure at TOC (tedizolid, 56.3% vs linezolid, 63.9%; difference, –7.6%; 97.5% CI: –15.7 to 0.5). In post hoc analyses, no single factor accounted for the difference in clinical response between treatment groups. Drug-related adverse events occurred in 8.1% and 11.9% of patients who received tedizolid and linezolid, respectively. Conclusions Tedizolid was noninferior to linezolid for day 28 ACM in the treatment of gram-positive ventilated HABP/VABP. Noninferiority of tedizolid for investigator-assessed clinical response at TOC was not demonstrated. Both drugs were well tolerated. Clinical Trials Registration NCT02019420.
- Subjects
PNEUMONIA-related mortality; PNEUMONIA; DRUG efficacy; STATISTICS; CONFIDENCE intervals; PHOSPHATASES; METHICILLIN-resistant staphylococcus aureus; GRAM-positive bacterial infections; NOSOCOMIAL infections; LINEZOLID; RANDOMIZED controlled trials; COMPARATIVE studies; STAPHYLOCOCCAL diseases; BLIND experiment; VENTILATOR-associated pneumonia; STATISTICAL sampling; DATA analysis; PATIENT safety
- Publication
Clinical Infectious Diseases, 2021, Vol 73, Issue 3, pe710
- ISSN
1058-4838
- Publication type
Article
- DOI
10.1093/cid/ciab032